
    
      The study is a multi-center, randomized, double-blind, placebo-controlled, parallel group
      study comparing 2 doses of inhaled R343 bid to placebo over 8 weeks in patients with mild to
      moderate allergic asthma. Patients who meet specific inclusion and exclusion criteria after
      an initial screening evaluation and a single-blind, run-in period will be randomized to
      receive either R343 or placebo.
    
  